Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Apr;23(4):482–485. doi: 10.1111/j.1365-2125.1987.tb03080.x

Evidence for polymorphic oxidation of sparteine in Japanese subjects.

T Ishizaki, M Eichelbaum, Y Horai, K Hashimoto, K Chiba, H J Dengler
PMCID: PMC1386100  PMID: 3580254

Abstract

The metabolism of sparteine which exhibits a genetic polymorphism in Caucasians was studied in 84 unrelated Japanese subjects. In contrast to a recent study where debrisoquine was used as a probe and no poor metabolizers could be observed in Japanese involving 100 subjects, two subjects had a urinary metabolic ratio of sparteine greater than 20 and thus were poor metabolizers of sparteine. The incidence of poor metabolizer phenotype of sparteine oxidation of 2% seems to be lower in Japanese as compared with various Caucasian populations where 5 to 10% are poor metabolizers of sparteine. However, this is not conclusive, because the 95% confidence interval of the observed frequency, 0.6 to 8%, covers the range reported in the literature for Caucasians.

Full text

PDF
483

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertilsson L., Dengler H. J., Eichelbaum M., Schulz H. U. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur J Clin Pharmacol. 1980 Feb;17(2):153–155. doi: 10.1007/BF00562624. [DOI] [PubMed] [Google Scholar]
  2. Clark D. W. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs. 1985 Apr;29(4):342–375. doi: 10.2165/00003495-198529040-00003. [DOI] [PubMed] [Google Scholar]
  3. Eichelbaum M., Bertilsson L., Säwe J., Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther. 1982 Feb;31(2):184–186. doi: 10.1038/clpt.1982.29. [DOI] [PubMed] [Google Scholar]
  4. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982 Jan-Feb;7(1):1–22. doi: 10.2165/00003088-198207010-00001. [DOI] [PubMed] [Google Scholar]
  5. Eichelbaum M. Polymorphic drug oxidation in humans. Fed Proc. 1984 May 15;43(8):2298–2302. [PubMed] [Google Scholar]
  6. Eichelbaum M., Reetz K. P., Schmidt E. K., Zekorn C. The genetic polymorphism of sparteine metabolism. Xenobiotica. 1986 May;16(5):465–481. doi: 10.3109/00498258609050252. [DOI] [PubMed] [Google Scholar]
  7. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  8. Eichelbaum M., Woolhouse N. M. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eur J Clin Pharmacol. 1985;28(1):79–83. doi: 10.1007/BF00635712. [DOI] [PubMed] [Google Scholar]
  9. Evans D. A., Harmer D., Downham D. Y., Whibley E. J., Idle J. R., Ritchie J., Smith R. L. The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J Med Genet. 1983 Oct;20(5):321–329. doi: 10.1136/jmg.20.5.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Inaba T., Otton S. V., Kalow W. Deficient metabolism of debrisoquine and sparteine. Clin Pharmacol Ther. 1980 Apr;27(4):547–549. doi: 10.1038/clpt.1980.77. [DOI] [PubMed] [Google Scholar]
  11. Jurima M., Inaba T., Kadar D., Kalow W. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol. 1985 Apr;19(4):483–487. doi: 10.1111/j.1365-2125.1985.tb02673.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nakamura K., Goto F., Ray W. A., McAllister C. B., Jacqz E., Wilkinson G. R., Branch R. A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 1985 Oct;38(4):402–408. doi: 10.1038/clpt.1985.194. [DOI] [PubMed] [Google Scholar]
  13. SUNAHARA S., URANOM, OGAWAM Genetical and geographic studies on isoniazid inactivation. Science. 1961 Nov 10;134(3489):1530–1531. doi: 10.1126/science.134.3489.1530. [DOI] [PubMed] [Google Scholar]
  14. Vinks A., Inaba T., Otton S. V., Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther. 1982 Jan;31(1):23–29. doi: 10.1038/clpt.1982.4. [DOI] [PubMed] [Google Scholar]
  15. Woolhouse N. M., Eichelbaum M., Oates N. S., Idle J. R., Smith R. L. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther. 1985 May;37(5):512–521. doi: 10.1038/clpt.1985.81. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES